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The aim of this study was to establish the criteria for methodology of cellular “anti-IGF-I” therapy of malignant tumours
and particularly for glioblastoma multiforme. The treatment of primary glioblastoma patients using surgery, radiotherapy, and
chemotherapy was followed by subcutaneous injection of autologous cancer cells transfected by IGF-I antisense/triple helix
expression vectors. The prepared cell “vaccines” should it be in the case of glioblastomas or other tumours, have shown a change of
phenotype, the absence of IGF-I protein, and expression of MHC-I and B7. The peripheral blood lymphocytes, PBL cells, removed
after each of two successive vaccinations, have demonstrated for all the types of tumour tested an increasing level of CD8+ and
CD8+28+ molecules and a switch from CD8+11b+ to CD8+11. All cancer patients were supervised for up to 19 months, the period
corresponding to minimum survival of glioblastoma patients. The obtained results have permitted to specify the common criteria
for “anti-IGF-I” strategy: characteristics sine qua non of injected “vaccines” (cloned cells IGF-I(−) and MHC-I(+)) and of PBL
cells (CD8+ increased level).
1.Introduction
Current treatment options for patients with advanced
malignant tumours, including brain tumour glioblastoma
(mortality approaching 100%), such as surgery, radiation,
or hormone therapy are limited in eﬃcacy; therefore the
search for new strategies: innovative chemotherapy [1],
use of inhibitors, including antibodies, antisense oligonu-
cleotides, short peptides, and other small molecules [2–4],
or cellular immune therapy [5] constitutes a permanent
challenge.
We have previously described the immune cellular/anti-
gene anti-IGF-I approach [4], targeting IGF-I, the growth
factor playing a principal role in the tumour growth
processes [6]. Such strategy of anti-gene, of antisense or
triple helix approach [7–9], has permitted to stop the devel-
opment of the following animal tumours: glioma, hepatoma,
melanoma and teratocarcinoma (containing three tissue
derivatives) as well as to treat human gliomas mediated
by immune antitumour CD8+ T cells induced in vivo by
injection of cellular “vaccines” presenting immunogenic
characteristics (expression of MHC-I) (Figure 1)[ 4, 10–12].2 Chemotherapy Research and Practice
The principal goal of this work—Phase I gene therapy of
glioblastoma—was to establish the criteria of methodology
for clinical trial based on principal results of previously
described studies—the immune antitumour phenomenon
observed in the antisense anti-IGF-I treatment of rat and
human gliomas, and signaled by the increase of CTL
CD8+ in the tumour tissue as well as in peripheral blood
lymphocytes [4]. In the present work, we have used the
strategy of combined antisense/triple helix technologies to
prepare the anti-gene anti-IGF-I “vaccines” and investigate
an immune response in treated patients with malignant
tumours expressing IGF-I. Comparatively, the tumours rep-
resentingthreetissuederivativeswereconsidered:principally
neuroectodermal-glioblastoma, entodermal-liver and colon
cancers, and mesodermal-cancers of ovary, uterus, and
prostate [4, 23, 24].
2.MaterialsandMethods
2.1. Ethical Consideration. Human experiments were con-
ducted in accordance with the Declaration of Helsinki
(1964). The experiment was conducted with the understand-
ing and the consent of the human subject. The responsible
Ethical Committees have approved the experiments.
The approval for the gene therapy clinical trial (based
on NIH clinical protocolno. 1602, Bethesda, Maryland, 24.
11. 1993), containing scientiﬁc basis of methodology, cell
therapy product standardization of preparation, detailed
clinical protocol including inclusion criteria and exclusion
criteria (i.e., HIV and EBV active infection), and the letter
of agreement, was administrated by the Bioethical Com-
missions of the L. Rydygier Medical University, Bromberg
(Bydgoszcz), Jagiellonian University, Cracow, Poland no.
KB/176/2001, 28. 06. 2002, and (no. KBET/184/L/2000, 21.
09. 2000), La Sabana University, Chia, Colombia, no. P
004-10, 15. 12. 2010, Cartagena’s University, Colombia, no.
3-19.10.2011, and registered by international Wiley Gene
Therapy Clinical Trial database, Stockholm, no. 635 and 636
(J Gene Med, updated 2002). The protocol was veriﬁed by
Ministry of Health, AFSSAPS Committee, Paris, France, 03.
06.2005,andbyNATOScienceprogram2003–2007(no.LST
980517).
2.2. Preparation of Cell “Vaccines”
2.2.1. Plasmids. The IGF-I antisense and triple helix tech-
nologies, both suppressing IGF-I expression, were used to
construct episome-based plasmids either pMT-Anti-IGF-I
expressing IGF-I RNA antisense, or pMT-AG inducing the
IGF-IRNA-DNAtriplehelix,comingfrompMT-EP“empty”
vector [10, 25]. The cassette contains the Epstein-BarrVirus
origin of replication and the gene encoding nuclear antigen
I, which together drive extrachromosomal replication. In the
pMT-AG triple helix, the cassette consists of a 23bp DNA
fragment cloned into the pMT-EP vector, which transcribes
athirdRNAstrandformingatriplehelixstructurewithinthe
target region of the human IGF-I gene (Figure 1). The triple
helix structure forming IGF-I RNA- DNA structure, giving
rise to used IGF-I triple helix gene therapy approach, was
largely described in previously published papers; moreover,
the experimental data in vitro accompanied by control
experiments constituted either by use of antisense technique
or by use of control “empty” vectors were also performed
[19, 25].
The vector and the cells transfected with these vectors
weretestedforthepresenceofDNAsequenceofEBVvirus—
in the vector, the 4.4Kb sequence of EBV is inserted. The
tests of PCR EBV have given the negative results (Texcell-
Institut Pasteur, ref. 114/01/1054D-02/07 and -01/03; report
27.03.1996). Although the testes were done in 1996, these
results are still valuable because the total sequence of used
vectors was never changed.
2.2.2.EstablishmentofPrimaryCellCultures. Thecancercells
were originated from surgically removed biopsies of pri-
mary malignant tumours as follows: glioblastoma (astrocy-
toma grade IV, glioblastoma multiforme), hepatocarcinoma
(diﬀerentiated adenocarcinoma), colon carcinoma (diﬀer-
entiated adenocarcinoma), ovary carcinoma (cystadeno-
carcinoma), uterus carcinoma (endometrial adenocarci-
noma), and prostate carcinoma (adenocarcinoma, cyto-
logic malignancy, grade III). Two cases of each malignant
tumour were investigated. Surgical resections [10]w e r e
done in the University Hospital of Bromberg (Bydgoszcz),
Poland. Primary cell lines originated from every biopsy were
established during 3-4 weeks [19], simultaneously in three
countries (Bromberg and Cracow, Poland, Paris, France, and
Cartagena, Colombia).
The removed cancer tissue material was vial to establish
the cell culture if the biopsy was used before 24 hours fol-
lowingsurgery.CellswereculturedinDMEM(GIBCO-BRL)
supplemented with 10% FCS, 2mM glutamine, 100U/mL
penicillin, and 100ug/mL streptomycin, at 37◦Ca n d5 %
CO2. In the case of glioblastoma and colon cancer, primary
human cell lines established previously (CWRU, Cleveland,
and Paul Brousse Hospital, Villejuif) have played a role
of “cell line controls” for veriﬁcations of IGF-I presence
(immunocytochemical reaction for IGF-I, using antibodies
anti-IGF-I, and conﬁrmed by RT-PCR), and MHC-I and B7
antigens absence (immunocytochemical or ﬂow cytometry
analysis using antibodies anti-MHC-I and anti-B7) [19, 26,
27].
RT-PCR (reverse transcriptase-polymerase chain reac-
tion) technique was applied as described earlier [27]. RNA
from cells was isolated using High Pure RNA Isolation
Kit (Roche Diagnostics GmbH no.1828665). The applied
components of RT PCR were used according Reverse Tran-
scription System Promega Corporation (no. A3500). The
following primers were used for RT PCR study of human
IGF-I:
forward primer IGF-I: GCATCTCTTCTACCTGGCG-
CTG, and reverse primer IGF-I: CAGGCTTGAGGGGTG-
CGCAATA (sequence according to “rgd” Human Genome
Database).
We notice that the eﬃciency rate in the in vitro establish-
ment of tumour cell lines was 100% [19, 27] and that thisChemotherapy Research and Practice 3
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Figure 1: Mechanism of anti-gene anti-IGF-I (antisense/triple helix) therapy of malignant tumours. The case of glioblastoma therapy:
hypothetically, the same mechanism should exist in the treatment of other tumours expressing IGF-I. The mechanism of antisense therapy
is a combination of an augmentation of the immune antitumour response and of an inhibition of signal transduction pathway that is
involved in the transformed phenotype of the tumour. Tumour cells are transfected in vitro with a vector encoding IGF-I cDNA in antisense
orientation, or with a vector inducing a formation of triple helix IGF-I structure. The transfected tumor glial cells, in absence of IGF-I,
become immunogenic-expressing MHC-I and B7 molecules, and apoptotic as follows. The expression of MHC-I is due to the presence
of TAP1; the expression of B7 is related directly with signal transduction pathway: TK/IRS/PI3K/PKC; the phenomenon of apoptosis
is also related with signal transduction pathway: TK/IRS/PI3K/AKT/Bcl2 [4, 13–18]. After in vivo injection, together with the antigen
presenting cells, APC, they activate the T CD8 (CD8CD28) lymphocytes inducing immune antitumour response against the malignant
glioma (expressing MHC-I) [4, 15, 19–22].
issue has not represented a limit in the number of patients
that could be enrolled in this study. In addition, the quality
control of the tumour cultured cells has concerned the
test for mycoplasma, endotoxin, and aerobic and anaerobic
bacteria.
2.2.3. Transfection of Cell Lines. Using both antisense and
triple helix anti-IGF-I expressing vectors, transfection was
done during 2-3 weeks, by either Ca++/Ph technique or
FuGENE 6 Transfection Reagent (Boehringer Mannheim)
[19]. 48 hours after transfection, the selection of transfected4 Chemotherapy Research and Practice
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Figure 2: Expression of IGF-I in primary human glioma cell line.
RT PCR technique. M—marker. 1—presence of IGF-I in parental
non transfected cells (200bp band of ampliﬁed DNA using IGF-
I primer; see Methods). 2—absence of IGF-I expression in cells
transfected with antisense anti-IGF-I vector. 3—absence of IGF-I
expression in cells transfected with triple helix anti-IGF-I vector.
cells was done in the presence of Hygromycin B (Boehringer
Mannheim) at a concentration of 0,005mg/mL. After one
week, concentration of hygromycin B was changed to
0,015mg/mL and progressively increased up to 0,15mg/mL
and maintained with each change of fresh medium over the
next 2-3 months. Two weeks after transfection, cell lines
derived of the same tumour were veriﬁed for absence of
IGF-I using immunocytochemistry technique, conﬁrmed by
RT PCR technique (Figure 2), and for presence of MHC-I
and B7 molecules using ﬂow cytometry analysis (Figure 3):
monoclonal antibodies, labeling human MHC-I (HLA),
MHC-II,CD80,andCD86(B7)antigenswereusedfordirect
immunostaining (Becton Dickinson Pharmingen) [19, 27].
The expression of IGF-I, MHC-I, and B7 in nontransfected
and transfected separately “antisense” and “triple helix”
cancer cell lines (Figure 2) was veriﬁed in the laboratories of
Bromberg and Krakow (Poland), Cleveland (USA), Villejuif
(France), and Medellin and Bogota (Colombia). The cell
lines transfected with “empty” vector have constituted a
negative control for both “antisense” and “triple helix” lines.
2.2.4. Cloning of Cells. The clones—transfected “anti-
sense” and “triple helix” cells—expressing MHC-I and B7
molecules were used for preparation of cell vaccines (in
general, 40–50% of clones were positively stained for MHC-
I, and 50–60% of clones were negative for MHC-I [11]).
The cultures of these clones, four weeks after transfection,
have presented about 50–60% of apoptotic cells, and 40–
50% of nonapoptotic cells which were IGF-I(−), MHC(+),
and B7(+) (Figure 1)[ 11, 19]. The apoptosis was veriﬁed as
described earlier [11, 28].
The established cell cultures were divided in three parts.
The ﬁrst part, 200000 cells, was used for the preparation
of cell membranes, prepared according to the technique of
Matlib et al. [29]. These cell membranes have constituted the
material for ﬁrst, noncell, “membrane vaccination”. When
the cells growing in culture were numerous enough, 3–5
million “antisense cells” and “triple helix cells”, respectively,
one part of them was used for “cellular vaccination”—
injection of 3 million of cells: 1.5 million of “antisense cells”
mixed with 1.5 million “triple helix cells”, and another part
was frozen as “back-up” in liquid nitrogen.
2.3. Vaccination of Cancer Patients. The principal clinical
trial concerned glioblastoma patients. Six patients in Uni-
versity Hospital of Bydgoszcz and six patients in CWRU
Hospital of Cleveland were treated, respectively. The patients
in Bydgoszcz were divided in three groups of two cases
each (considering that this clinical trial was the beginning
of Phase 1 presenting a limited number of patients, the
statistical analysis was not included in the study). In every
group the age of patients was about twenty years and sixty
years, respectively (the individual characteristics are not a
subjectofthepresentedwork).Intheﬁrstgroup,thepatients
treated by surgery, radiotherapy, and chemotherapy (low
dose chemotherapy-temozolomide 75mg/m2/day, applied
during the period of radiotherapy) have followed three
successive subcutaneous injections of cellular membranes
isolated from IGF-I antisense/triple helix-transfected cells
(membrane vaccinations). In the second group after surgery,
radiotherapy, and chemotherapy (low dose), the ﬁrst mem-
brane injection was followed by two successive subcutaneous
“cellular vaccinations” composed of IGF-I antisense/triple
helix-transfected cells—containing both apoptotic and non-
apoptotic cells. The third group, a control group, was treated
by surgery, radiotherapy, and chemotherapy. On the other
side, six glioblastoma patients in Cleveland were treated by
unique therapy: surgery, radiotherapy, and chemotherapy
were followed by successive subcutaneous “cellular vac-
cinations” composed of IGF-I antisense-transfected cells
containing both apoptotic and non apoptotic cells. In
parallel, the patients with cancers of liver, colon, uterus,
ovary, and prostate (Bydgoszcz) have followed the treatment
composed of surgery, radiotherapy, and successive “cellular
vaccinations” (see Section 3.3).
The injections were done with interval of four-ﬁve
weeks. 48 hours before every vaccination, the membrane
or cell pellets (“membrane” or “cellular” therapies) were
irradiated with 5000 cGy gamma (Co60 or Cs137) [10]. The
membranes or cells were injected subcutaneously, into the
left arm of operated cancer patients, in 1mL of PBS solution.
The blood was collected three times: before vaccinations
and after every of two cell vaccinations (2-3 weeks after the
second and the third injection).
FlowcytometricanalysisofPBLcellswasdoneasfollows:
peripheral blood lymphocyte (PBL) typing was performed
after hemolysis by incubation of peripheral blood with mon-
oclonal antibodies against the cell antigens: CD3, CD4, CD5,
CD8, CD8+ 11b+,C D 8 +11b−,C D 8 +28+, CD19, CD3−(16 +
56) + (NK), CD25, CD44, and CD45 (Becton Dickinson
Pharmingen, direct immunostaining). Paraformaldehyde-
ﬁx edcellswereexaminedinF A CSscanBDcytometer .Double
direct immunotyping with pairs of monoclonal antibodies
conjugated with FITC and PE were used. Lymphocyte gateChemotherapy Research and Practice 5
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Figure 3: Expression of MHC-I in an established primary human glioma cell line. Flow cytometry analysis (FACScan Becton Dickinson).
Panel left: parental nontransfected cells. Panel right: cells transfected with both antisense and triple helix anti-IGF-I vectors.
was deﬁned according to the CD45 back gating. Data were
presented as percentage of positive cells [4, 19]. The PBL
labelling of cells was done simultaneously in two laboratories
(Bydgoszcz and Villejuif).
3. Results
3.1. Preparation of Cell “Vaccines”. The primary human cell
lines derived from all types of cancer biopsies—primary
tumours—were successfully established following the tech-
nique described earlier concerning glioblastoma, hepatoma,
and colon cancer [4, 19, 26]. Each cell line was subcloned
to obtain IGF-I positive clones (the percent of IGF-I positive
cells in the human cell lines ranged from 50 to 70%). All the
primary cell lines were also transfected, showing a change of
phenotype. The examples of primary cell lines as well as of
transfected cell lines of ovary and prostate cancers are shown
in Figure 4.
IGF-I expression was veriﬁed before and after transfec-
tion of all types of cancer cells: using RT PCR technique,
analysis of RNA of cancer cells four weeks after transfection
was compared to RNA of parental cells (Figure 5). Then the
transfectedcells (not expressing IGF-I), serving as “vaccines”
for diﬀerent types of cancers, were cloned to obtain MHC-
I positive cell lines as previously described in the case of
human glioblastoma-transfected cells [19]. The transfected
MHC-I positive cancer cells have also expressed B7 antigen
with exception of hepatoma-transfected cells as described
earlier [11]. Human cancer cells transfected with “empty”
vector, pMT/EP, serving as negative control, were stained
positively for IGF-I and negatively for MHC-I and B7.
3.2. PBL Typing in Treated Cancer Patients. Clearcut phe-
notypic changes in peripheral blood lymphocytes (PBLs)
were observed in all cancer diseases treated with “cellular
therapy”: after the ﬁrst cell vaccination, the increase of
CTL CD8+, particularly CD8+11b−, was observed. There
was a characteristic switching from CD8+11b+ to CD8+11b−
which was practically not signiﬁcant in the group of
“membrane therapy” applied for two glioblastoma patients.
This increasing switching was also observed after the second
cell vaccination in all treated cancers. Moreover, the PBL
cells have demonstrated, in all types of tumour diseases, an
increasing expression of cell surface markers CD8+CD28+
conﬁrming the eﬀectiveness of “cellular therapy” (Figures
6(a), 6(b), 6(c), 6(d), 6(e),a n d6(f)). The results concerning
other studied CD molecules as CD3 or CD19 and CD45
(data not shown) were no signiﬁcant in all treated cancers;
in the case of CD4 slightly decreased values were registered
(as only two cases of each tumour were studied, these
observations not be statistically valuable). That is important
to add that no signiﬁcant change in CTL CD8 level was
observed as well before and after the surgery and before
and after radiotherapy treatments as compared to “cellular
therapy”. (The control “empty” vector, without antisense
anti-IGF-I cDNA, used to prepare “vaccines” in animal
models previously described, has never shown inﬂuence for
immune antitumour response [32, 33].)
3.3. Median Survival of Treated Glioblastoma Patients. The
results obtained in the University Hospital of Bromberg
were as follows: two glioblastoma patients included in
the group of “cellular therapy” have survived 19 and 24
months, respectively (beginning from day 0—diagnosis
of malignant glioma, followed by surgery, radiotherapy,
and antisense/triple helix cell injections). Two glioblastoma
patients included in the group of “membrane therapy”
have survived 9.5 and 10 months, respectively, starting
from surgery followed by radiotherapy and injection of
cell membranes. The results observed in the group of
glioblastomapatientstreatedwith“membranetherapy”were
not so diﬀerent from those obtained in the third group6 Chemotherapy Research and Practice
(a) (c)
(d) (b)
Figure 4: Examples of in vitro culture of primary human cancer cells derived from surgical biopsies. (a) and (c) Primary ovary
cystadenocarcinoma-derived cells. (b) and (d) Primary prostate adenocarcinoma-derived cells. Parental ovary cancer cells (a) and prostate
cancer cells (b) are attached eﬃciently in the fourth day of culture (arrows). “Antisense/triple helix” anti-IGF-I ovary cancer cells (c) and
prostate cancer cells (d), both twenty days after transfection, form the established lines characterized often by the clusters of round apoptotic
cells, becoming progressively small (c, arrow; d, arrow up). They are accompanied by nonapoptotic and more voluminous cells (d, arrow
down) presenting generally elongated shape (c and d). The transfected cells are always diﬀe r e n tf r o mn o n t r a n s f e c t e dp a r e n t a lc e l l s( a ,b ) ,a s
it was demonstrated previously in cases of human glioma and hepatoma cell lines established from primary tumours of glioblastoma and
hepatocarcinoma [30, 31] X400.
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Figure 5: Expression of IGF-I in human cancer cell lines. RT PCR
technique. M—marker. Lines 1 to 6—presence of IGF-I in parental
nontransfected cancer cell lines derived from 1—glioblastoma,
2—hepatocarcinoma, 3—colon adenocarcinoma, 4—ovary cyst
adenocarcinoma, 5—uterus endometrial adenocarcinoma, and 6—
prostate adenocarcinoma (200bp band of ampliﬁed DNA using
IGF-I primer; see Section 2. Lines 7 to 12—absence of IGF-I
expression in cancer cells transfected with both antisense and triple
helix anti-IGF-I vectors: 7—glioblastoma, 8—hepatocarcinoma,
9—colon adenocarcinoma, 10—ovary cyst adenocarcinoma, 11—
uterus endometrial adenocarcinoma, and 12—prostate adenocarci-
noma.
treated by classical therapy; in the last group median survival
was as 10 and 11 months. For this reason, admitting that the
group of glioblastoma patients treated with antisense/triple
helix cell injection has given the signiﬁcant results, all other
cancer patients (age 20–65 years: two cases of liver, colon,
ovary, uterus, and prostate cancer diseases) were treated,
after surgery and radiotherapy with this type of “cellular
therapy”. Moreover the period of 19 months was chosen as
the end of clinical observations in all treated cancer patients.
At 19 months, all these cancer patients were alive and the
treatments were well tolerated (we do not include the details
of clinical observations concerning diﬀerent types of treated
cancers, because it is not the subject of this work). The only
secondary observed eﬀect including glioblastoma patients
was that of increased temperature up to 38-39◦C persisting
during two-three days after every of cell vaccination.
Among the patients treated in USA (University Hospitals
of Cleveland) with anti-gene anti-IGF-I “cellular therapy”
(two cell injections), two of the treated patients forming
a group of maximum median OS have both survived
19 months. The other group of three patients have not
responded so positively to the therapy, showing the median
survival compared with that of “membrane” therapy. The
therapy done in USA has shown that the number of cell
vaccinations (between one and four) was not related to the
median OS. Concerning serial MRI/CT performed in USA
patients: 1-2-month intervals before vaccine showed contin-
uous growth of the intracerebral tumour. MRI one month
after vaccination showed ﬁrst evidence of an unequivocalChemotherapy Research and Practice 7
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Figure 6: Flow cytometric “FACS” peripheral blood lymphocyte CD marker patterns following cellular gene therapy in human cancers. (a)
glioblastoma multiforme; (b) hepatocarcinoma; (c) colon adenocarcinoma; (d) ovarian carcinoma; (e) uterine adenocarcinoma; (f) prostate
adenocarcinoma. CDmoleculeswerelabelled inperipheralbloodlymphocytes(PBLs)obtainedfromprevaccinated and“vaccinated” cancer
patients. Each of the ﬁrst column corresponds to data obtained before vaccinations; each second and third column corresponds to data
obtained after one and two successive cellular vaccinations (IGF-I antisense/triple helix cells). Two cases of each of the designated cancers
were examined (bar graphs represent the median value of the two cases). Data are expressed as percent of positive cells when compared to
the isotype control. Diﬀerence in percentage of CD8+ CD11b− and CD8+ CD28+ subpopulations before and after vaccination was strongly
signiﬁcant with a range of P from 0.001 to 0.02 according to the Student’s t-test and weakly signiﬁcant concerning the decreasing CD8+
CD11b+ subpopulation from the relevant patients. The P value for CD8+,C D 8 +28+, and CD8+11b− (below 0.01) is illustrated in the
bar graph for statistical signiﬁcance. (The original FACS data concerning PBL cells are in the archives of Collegium Medicum of Nicolas
CopernicUniversity,Bromberg,Poland;FACSdata(n = 504)correspondingtothelabelingofCD3,CD4,CD5,CD8,CD8+11b+,CD8 +11b−,
CD8+28+, CD19, CD3−(16 + 56) + (NK), CD25, CD44, and CD45.)8 Chemotherapy Research and Practice
decreaseinsizeoftumoursviewedbyradiologyinUniversity
Hospitals of Cleveland. Moreover, all patients treated in USA
had advanced disease with cerebral edema at the time of ﬁrst
treatment with vaccine and also were receiving treatment
with high dose of decadron or related steroids to reduce
the eﬀect of CNS edema. This of course has caused further
jeopardytotheimmunesystemandcanexplaintherelatively
negative results in three last treated cases.
4. Discussion
New ways of treating malignant tumours, and very eﬃcient
chemotherapies in particular, are constantly being investi-
gated; the best example is that of temozolomide introduced
in glioblastoma treatment by Stupp et al. [1]. This type of
chemotherapy has permitted to increase the median survival
up to 15–18 months of glioblastoma patients, showing a
real success comparing to current 8–11 months of median
survival using surgery and radiotherapy only [1, 2, 4].
The gene therapy may represent a novel approach for
cancer therapy. The elucidation of the molecular biology
of cancer cells in recent years has progressively identiﬁed
the diﬀerent molecular pathways altered in various cancers.
Activation of the PI3K/AKT/GWK3/GS pathway is mediated
by some tyrosine kinase receptors, under the control of
several growth factors and cytokines as EGF, PDGF, VEGF,
TGFbeta,CSF,andespeciallyIGF-I,whosereceptor,IGF-I-R,
playsaprincipalroleinthetumourgrowthprocess[4,6,34].
Formostofthepathwaysthathavebeendisclosed,ithasbeen
a problem to develop selective molecules having a relevant
clinical impact in malignant diseases, including uncured
glioblastoma [35]. To target speciﬁc genetic defects, the
antisenseoligonucleotideshavebecomeoneoftheimportant
anticancer approaches used in clinical trials [36].
The glioblastoma, as well as other malignant tumours,
was recently successfully treated by antisense therapy target-
ingTGFbeta,usingeitherantisenseanti-TGFbetaexpressing
vector [37] or particularly applying the oligodeoxynu-
cleotides [38, 39]. Using phosphorothioate TFG beta 2
antisense oligonucleotides (AP-12009), an international
phase II/III study was initiated in patients with TGF beta-
overexpressing tumours such as high-grade gliomas, and by
2005-2006, the trial was ongoing in over 140 patients with
anaplastic astrocytoma (AA) or glioblastoma; the treatment
was very well tolerated. In 2007, at that time overall
survival was 24 months, and in the control group, survival
was 20 months [38, 40]. Results from the clinical trials
concerning other tumours overexpressing TGF beta were
also recently published (pancreatic carcinoma, metastatic
melanoma,oradvancedcolorectalcarcinoma);thetreatment
w a sw e l lt o l e r a t e di na l lt y p e so ft u m o u rd i s e a s e s[ 38].
Other antisense approaches of malignant tumour treatment
have been developed recently, since 2001, especially those of
antisense anti-IGF-I-Receptor [6, 41]. AS IGF-I-R strategy of
treatment of glioblastoma [41] was not continued. It seems
that this therapy could be more eﬃcient if the cell “vaccines”
were prepared after cloning of IGF-I-R antisense cells for
MHC-I expression.
In anti-gene anti-IGF-I approach, we have applied both
antisense and triple helix technologies, permitting to stop
simultaneously the expression of IGF-I on translation and
transcription levels [4]. Moreover, in vivo AS IGF-I approach
was also developed [42]; 45 patients with PHC were
cotransfected in vivo with antisense IGF-I expression vector
and sense B7.1 expression vector. At two years following
treatment of PHC stage II, there was marked reduction in
t u m o u rr e c u r r e n c e — f r o m6 2t o2 0 % .
In antisense anti TGF-beta technique as well as in
anti-IGF-I and IGF-I-R approaches, the immune antitu-
mour response was signalled as a principal mechanism of
antisense technology inhibiting growth factors and their
signalling pathway [19, 37]. The mechanism of antisense
therapy targeting growth factors and their receptors is a
combination of an augmentation of the immune antitumour
response and of an inhibition of the signal transduction
pathway—PI3K/AKT/GWK3/GS—that is involved in the
transformed phenotype of the tumour [4, 13]. As far as
PI3K/AKT/GWK3/GS pathway (in relation with glioma) is
considered, it was recently demonstrated that in experimen-
tal antisense antiglycogen synthetase, GS, tumour therapy,
the transfected AS GS cells were also immunogenic (MHC-I
expression) [13, 14]. Anyway in AS GS strategy an immune
antitumour response was not as striking as when using
AS IGF-I approach. This shows that AS IGF-I appears
as a dominant tool for the arrest of tumour progression.
Moreover, targeting IGF-I instead of IGF-I receptor seems
more eﬃcient: because of downstream elements involved
in the IGF-I-R transduction pathway, signals from IGF-I-
R can be inappropriate or exaggerated [34]. Nevertheless, if
crosstalk of IGF-I’s related diﬀerent pathways is considered,
IGF-I, through its binding to IGF-I-R, which activates
PI3K/AKT transduction cascade, has been reported to block
the apoptosis pathway (IRS/PI3K/AKT/Bcl or AKT/GSK3 or
Ca2+ orcaspases)[4,6].TheﬁnalresultofASIGF-Iapproach
including the TK/PI3K/AKT pathway elements inhibition is
animmuneresponsemediatedinvivobylymphocytesTCD8
and APC cells [4]. As to PI3K/AKT/GWK3/GS pathways of
IGF-I AS or TGFbeta AS therapies, we cannot avoid the
relation with PI3K/PKC/RAF/MAPK chain, and we cannot
exclude that the inhibition of TK/PI3K/AKT pathway using
AS IGF-I approach can be reinforced by “side” eﬀect of
MAPK inhibition [4]. The inhibitors of RAF targeting the
ATP binding site, as well as the inhibitors of MAPK at a
non-ATP site, were also introduced in cancer clinical trials
[32, 43].
UsingdescribedhereIGF-Iantisense/triplehelixstrategy,
all treated patients have well tolerated the three injections
of transfected cancer cells. The PBL cells have shown
an increase in CD8+CD28+ molecules with a character-
istic switching from CD8+11b+ to CD8+11b− phenotype,
observed after two cell vaccinations, reﬂecting the enhanced
activation of cytotoxic T-cells in blood. These results con-
cerning the switching CD8+11b+ to CD8+11b− in diﬀerent
treated tumours have conﬁrmed previously obtained data in
glioblastoma and hepatoma treatment using antisens anti-
IGF-Iapproach[4,28].Theworkinprogresshasalsoshown,
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percentage of T CD25 (interleukin-2 receptor), in the
context of CD4, which has conﬁrmed the results obtained
in glioblastoma treatment [4]. (Currently we are engaged
in Phase II with 60 patients treated for diﬀerent types
of cancers mentioned earlier, including lung and stomach
cancers.) The only secondary observed eﬀect was increased
temperature, 38-39◦C, conﬁrming the immune response
induced by antisense/triple helix “vaccines”. The speciﬁcity
of immune response was every time conﬁrmed as follows. As
demanded by approved clinical trials (see higher mentioned
Bioethical Committees from 1993 to 2010), the removed
PBLs of patients were tested in vitro for immune response
after contact with autologous tumor cells to demonstrate
antitumor activation throught high percentage of speciﬁc
T cells observed after vaccination compared to controls—
before vaccination (the tumoral cells were labeled with Cr51
before the test of lyses in the presence of CTL cells [33, 44];
data not shown).
Regarding injection of cell membranes, the switching
mentioned earlier was not signiﬁcant. The challenge of
injection of membranes, isolated from IGF-I antisense/triple
helix-transfectedcellsexpressingMHC-I,hasprovedthatthe
whole transfected cell population is necessary to produce
an in vivo antitumour eﬀect. At ﬁrst, the cytoplasm of the
transfected cells contains the IGF-I antisense RNA and IGF-I
triple helix RNA-DNA structures constituting the principle
of anti-gene cellular therapy [25, 45]. Next, the cellular ther-
apy described here has shown that both cell populations, as
well MHC-I and B7 expressing transfected cells as apoptotic
cells, are necessary to induce in vivo an immune antitumour
responseinvolvingAPCactivatingCD8+ Tcells[4,11,30,45,
46]. (It was previously demonstrated that doubly transfected
cells, using antisense anti-MHC-I and anti-B7 vectors, lose
their apoptotic and immune antitumour characters [19]. It
was, this way, shown that both processes, immunogenicity
(MHC-I and B7 expression) and apoptosis, “work” together
[11, 19, 31].) On the other side we have previously compared
the eﬃciency of gene therapy—using the injection of IGF-I
AS nucleotides, and that of described here “cellular therapy”
much more promising. In gene therapy approach, after the
injection of IGF-I AS nucleotides directly to the tumor, the
cancer cells internalizing AS nucleotides could not become
immediately immunogenic to induce the rapid immune
response, and for the same reason to develop the eﬃcient
apoptosis. Moreover, in the gene therapy, the cotransfection
with B7 expression vector was necessary to reinforce the
immune response [28, 42].
As far as the relationship between anti-gene anti-
IGF-I technology and immunogenicity is considered, the
absence of IGF-I synthesis in “antisense-” and “triple-helix”-
transfected cells could lead to a compensative increase in
IGF-I receptor (tyrosine kinase); IGF-I and IGF-II present in
foetal calf serum of culture medium, as well as intracellular
IGF-II can interact with the type I receptor [47]. Indeed, the
increase of IGF-I receptor level could explain the expression
of B7. There is a known relation between the signal
transduction pathway of tyrosine kinase and the induction
of B7 molecules: enhancement in B-7 costimulation through
a cAMP mechanism linked to tyrosine kinase of the CD 28
receptor has been previously reported [15]. (The costimula-
tory B7 molecule in antigen presenting cells (APCs) is bound
to the counter-receptor CD28 and/or CTLA4 expressed
on the T-cells [20, 48, 49].) B7 was present in diﬀerent
antisense and triple helix anti-IGF-I transfected cancer cells
but absent in transfected human hepatoma and in previously
described murine hepatoma [47]. Those results have also
demonstrated that the expression of MHC-I in human-
transfected hepatoma cells was much higher than that in
transfected human glioma cells. This strong expression of
MHC-I in human-transfected hepatoma lines (5 times,
compared to human-transfected glioma lines) could explain
that the presence of MHC-I was suﬃcient to induce T CD8
lymphocytes response in the absence of B7 antigen [28]. To
summarizetheimmuneantitumourmechanismofanti-gene
anti-IGF-Istrategy,thisaspectwaspublishedpreviously(i.e.,
[4, 28]). As far as largely studied glioma treatment is con-
sidered, and similarly other concerned tumours, the mech-
anism concerns the reaction between activated lympho-
cytes expressing CD8CD28 and immune molecules MHC-
I and B7. The following chain reaction could occur: cul-
tured cloned glioma cells (IGF-I(+), MHC-I(−), B7(−)) ⇒
cultured transfected anti-gene IGF-I cells (IGF-I(−), MHC-
I(+), B7(+)) ⇒ injection (glioblastoma patients) ⇒ induc-
tion of CTL CD8(+) CD28(+) ⇒ destruction of injected
transfected anti-gene IGF-I cells (IGF-I(−), MHC-I(+),
B7(+)), and arrest of a solid glioma tumour (IGF-I(+/−),
MHC-I(+), B7(+)) (see also caption of Figure 1).
The immune criteria of used vaccines are strongly related
to the preparation of cancer cells to be used as vaccine.
Cancercellscultivatedunderstemcell-permissiveconditions
morecloselyreﬂectthetumoroforigin,includingthegenetic
proﬁle, than the parental tumor adherently growing cells
under conventional cultivation conditions [50, 51]. In our
experimental clinical trial, to avoid this eﬀect of “contamina-
tion” increased by numerous passages, the primary cancers
cells and transfected cancer cells were systematically cloned
after every passage to obtain in vitro, in the ﬁrst case 100%
IGF-I(+), MHC-I(−), and in the second case 100% IGF-
I(−), MHC-I(+) expression. The vaccines prepared with no
cloned cells (both cancer cells and transfected cancer cells)
did not induce the immune response in vivo in animals and
in patients.
Moreover, to produce their immune antitumour eﬀect,
the vaccines were composed of—criteria sine qua non— the
mixture of higher characterized cancer-transfected cells and
of cancer cell-derived apoptotic cells.
We need to add that if the all clinical results concerning
this work could be cited, we would be obliged to give the
summary of clinical data concerning 42 cancer patients
and their laboratory data analyzed in this paper (Bromberg
and Cleveland), including corresponding original FACS of
PBL cells labeling of every patient. The article concerning
only clinical results of every patient (clinical data of treated
cancerpatientsareinarchivesoffourhospitals,inBromberg,
Cracow, Cleveland, New York, Shanghai, and Bangkok; 70
patients only in Bromberg) including detailed inclusion and
exclusioncriteria,clinicalandlaboratorydata—PCRandRT
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factors, and MHC-I and B7 molecules; and blood test of
every patient—, will be published as separate article with
obligatory statistics, not treated in the presented manuscript.
5. Conclusions
Our presented work concerns the criteria established for
methodology of anti-IGF-I gene therapy analyzing our dif-
ferent previous basic and clinical results obtained in Europe,
USA, and Asia, following our NATO science program (see
Acknowledgment), and published recently [4, 27, 28], per-
mitting to start Phase I and II in South America (Colombia)
and Africa (Senegal). This way we have established the
common criteria for selection of vaccines (expression of
IGF-I, MHC-I, B7) and of PBL cells markers (CD8+-related
molecules) in patients presenting the arrest of growing
tumours.Thevarioustherapiesinthetreatmentofcancerare
still experimental [52]. A number of strategies for inhibiting
gene expression have been developed including the triple
helix approach, antisense cDNA, and oligodeoxynucleotides.
Among the new strategies in the eﬀorts of treating malignant
tumours expressing diﬀerent growth factors, and more
speciﬁcally IGF-I, TGF beta, VEGF, or EGF [3, 6, 35, 37],
the anti-gene therapy approach, either antisense or triple
helix, appears as a promising solution [39]. Although in
the presented work only limited numbers of glioblastoma
patientsweretreated,theclinicalresultsobtainedarepositive
(minimum survival has reached 19 months). The anti-
gene anti-IGF-I therapy, giving a strong immune antitu-
mour response in diﬀerent comparatively studied tumour
diseases, presents all characteristics of cell immunotherapy
(CD8+and CD28+ expression in T lymphocytes, and MHC-
I and B7 expression in “vaccine” cells) including apoptotic
phenomenon [4, 15, 45, 53]. We suggest that anti-gene
cell therapy, giving comparable results to those of currently
applied chemotherapy, inhibitors, or antibodies [1, 2, 4, 54],
could be used either alone [39, 55] or as combined therapies,
thatis,antisensestargetingsimultaneouslydiﬀerentelements
of growth factors signalling pathway [13, 14, 32, 43], or as
antisense/chemotherapy.Thecombinedanticancerstrategies
considering the role of immune antitumour response [35,
56–62], including study of control CD8(+) T-cell eﬀector
functions [63], new tools of cell transfection [64]a n d
especially the search for new oncoproteins [65], and growth
factor targets [6, 14, 35, 66, 67], appear as the near future
challenge. Among growth factors, targeting IGF-I system in
relation with cancer therapy constitutes a permanent basic
and clinical research [68–70].
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